AgingPhase 2NCT07871162
Fisetin for Improving Vascular Function in Older Adults: A Phase II Clinical Trial
A Phase 2 study testing Fisetin in people with Aging and Endothelial Dysfunction, run by University of Colorado, Boulder at 1 site in United States.
Trial summary
Aging is associated with the development of vascular dysfunction, which increases the risk for cardiovascular disease. This clinical trial will assess if supplementation with the natural compound fisetin can improve vascular endothelial function in older adults. Read more about this study
- Who is it for?
- Ages 65 years and olderHealthy volunteers can take part
- Conditions the study is for
- Aging, Endothelial Dysfunction, Cellular Senescence
- What is being tested?
- Fisetin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 136 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2026to Jun 2031
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- Healthy volunteers accepted
- Older adult
Who may be able to join
- Age 65 years or older
- Women must be postmenopausal
- Body mass index (BMI) <40 kg/m2
- Willing to accept random assignment
- Weight stable in the prior 2 months (<2 kg weight change) and willing to remain weight stable throughout the study
- Ability to understand study procedures and to comply with them for the entire length of the study
- Absence of established, serious, unstable, chronic clinical disease (e.g., unstable cardiovascular disease) that would make it unsafe for the individual to participate in the trial as determined by trial physician of record.
Who cannot join
- Inability to refrain from alcohol for 24 hours prior to outcome assessment, alcohol dependence or abuse
- Individuals taking fisetin, quercetin, luteolin, Dasatinib, piperlongumine or Navitoclax (supplements or drugs with possible senolytic effects) within 6 months prior to baseline testing as reported during medication review during screening. Should new research reveal other dietary supplements or drugs with potential senolytic effects, their use will be evaluated, and their use may lead to exclusion of the participant by the principal investigator (PI)
- New use of regular cardiovascular-acting medication which, in the opinion of the PI, affects the outcomes of the study within 3 months prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 3 months of regular use)
- Chronic use of a dietary supplement which, in the opinion of the PI, affects the outcomes of the study, within 1 month prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 1 month of regular use)
- Active malignancy (including myeloma) or malignancy that was active within 5 years prior to baseline testing as reported during Medical History and Physical and/or on study screening forms
- Inability or unwillingness of individual to give written informed consent
Show all 10Show fewer
- Current or past participation within 3 months in another clinical trial that, in the opinion of the PI, would affect the outcomes of the study
- Blood donation within 8 weeks prior to baseline testing; unwillingness to abstain from blood donation during the study and for 8 weeks after study completion
- Resting blood pressure >160 mmHg systolic or >100 mmHg diastolic.
- Regular vigorous aerobic/endurance exercise (>6 bouts/week at a moderate-high intensity)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Colorado Boulder
Boulder, Colorado, 80309
Sarah Haydu, 303-735-6410, fisetintrial@colorado.edu
About this study
Official title: Targeting Cellular Senescence With Fisetin for Improving Vascular Endothelial Function in Older Adults
Aging is associated with the development of vascular dysfunction, which increases the risk for cardiovascular disease. This clinical trial will assess if supplementation with the natural compound fisetin can improve vascular endothelial function in older adults. The clinical trial will also assess if any effects of fisetin on endothelial function are associated with reduced cellular senescence. The study will also evaluate safety, tolerability and adherence with fisetin treatment.
- Conditions
- Aging, Endothelial Dysfunction, Cellular Senescence
- Being tested
- Fisetin, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FisetinDietary supplement
Fisetin will be administered in an intermittent manner with six three-day dosing periods at a dose of 2 mg/kg/day separated by two weeks.
PlaceboOther
Placebo capsules identical in appearance to fistin capsules will be administered in an intermittent manner with six three-day dosing periods separated by two weeks.
| Study group | Role | What they receive |
|---|---|---|
| Fisetin | Experimental | Not described Receives: Dietary Supplement: Fisetin |
| Placebo | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in endothelial function at 3 months
Brachial artery flow-mediated dilation
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2026
- Study startNov 2026 (estimated)
- Primary completionMar 2031 (estimated)
- Study completionJun 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 136 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Colorado, Boulder
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Principal investigator, Matthew Rossman, University of Colorado, Boulder
- Investigators
- Matthew J Rossman, PhD, Principal investigator, University of Colorado, Boulder
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07871162
- Sponsor's protocol ID
- 26-0526
- Other IDs
- R01AG094826
- Status last verified
- Oct 2026
- First submitted
- 6 Oct 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Targeting Cellular Senescence With Fisetin for Improving Vascular Endothelial Function in Older Adults
- ClinicalTrials.gov ID
- NCT07871162
- Acronym / sponsor ID
- 26-0526
- Conditions
- Aging, Endothelial Dysfunction, Cellular Senescence
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 136 participants (estimated)
- Lead sponsor
- University of Colorado, BoulderUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- Nov 2026 (estimated)
- Primary completion
- Mar 2031 (estimated)
- Study completion
- Jun 2031 (estimated)
- First posted
- 13 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aging is associated with the development of vascular dysfunction, which increases the risk for cardiovascular disease. This clinical trial will assess if supplementation with the natural compound fisetin can improve vascular endothelial function in older adults. The clinical trial will also assess if any effects of fisetin on endothelial function are associated with reduced cellular senescence. The study will also evaluate safety, tolerability and adherence with fisetin treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fisetin | Experimental | Dietary Supplement: Fisetin |
| Placebo | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
Key inclusion criteria (7 listed)
- Age 65 years or older
- Women must be postmenopausal
- Body mass index (BMI) <40 kg/m2
- Willing to accept random assignment
- Weight stable in the prior 2 months (<2 kg weight change) and willing to remain weight stable throughout the study
Key exclusion criteria (10 listed)
- Inability to refrain from alcohol for 24 hours prior to outcome assessment, alcohol dependence or abuse
- Individuals taking fisetin, quercetin, luteolin, Dasatinib, piperlongumine or Navitoclax (supplements or drugs with possible senolytic effects) within 6 months prior to baseline testing as reported during medication review during screening. Should new research reveal other dietary supplements or drugs with potential senolytic effects, their use will be evaluated, and their use may lead to exclusion of the participant by the principal investigator (PI)
- New use of regular cardiovascular-acting medication which, in the opinion of the PI, affects the outcomes of the study within 3 months prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 3 months of regular use)
- Chronic use of a dietary supplement which, in the opinion of the PI, affects the outcomes of the study, within 1 month prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 1 month of regular use)
- Active malignancy (including myeloma) or malignancy that was active within 5 years prior to baseline testing as reported during Medical History and Physical and/or on study screening forms
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FisetinFisetin will be administered in an intermittent manner with six three-day dosing periods at a dose of 2 mg/kg/day separated by two weeks. | Dietary supplement | Fisetin |
| PlaceboPlacebo capsules identical in appearance to fistin capsules will be administered in an intermittent manner with six three-day dosing periods separated by two weeks. | Other | Placebo |
Primary outcome
Change from baseline in endothelial function at 3 months
Time frame: 3 months
Brachial artery flow-mediated dilation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
Related trials for Aging
RecruitingObservational study
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Aging
Not yet recruitingPhase 2
Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV
Epigenetic Aging
Not yet recruitingObservational study
China Healthy Aging and Fitness Longitudinal Study
Physical Fitness, Aging
Not yet recruiting
Effects of Different Amounts of Plyometric Exercise Without Jumping in Physically Inactive Older Adults
Sedentary Behavior / Physical Inactivity, Aging
RecruitingObservational study
Brain Activity During Complex Walking in People With Atypical Parkinsonian Syndromes
Gait Disorders, Neurologic, Atypical Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Matthew J Rossman, PhD principal investigator
University of Colorado, Boulder
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Fisetin in people with Aging and Endothelial Dysfunction, run by University of Colorado, Boulder at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sarah Haydu (303-735-6410, fisetintrial@colorado.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in endothelial function at 3 months (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.